NeurAxis, Inc. commercializes neuromodulation therapies for chronic and debilitating conditions in children and adults. The company’s proprietary IB-Stim product uses Percutaneous Electrical Nerve Field Stimulation, or PENFS, and is FDA cleared for functional abdominal pain associated with irritable bowel syndrome, functional dyspepsia, and FD-related nausea symptoms in patients 8 years and older.
Recurring NeurAxis news includes FDA clearance updates, reimbursement and coding developments, medical policy coverage decisions, commercial access through payer and government channels, and adoption of PENFS in clinical practice. Company updates also cover quarterly financial results, business update calls, preferred stock dividends, equity and balance-sheet activity, and changes involving licensed neuromodulation assets.
NeurAxis (NYSE American: NRXS) declared a stock dividend on its Series B preferred stock on April 10, 2026. Holders of record as of April 21, 2026 will receive common stock based on accrued unpaid dividends divided by $2.38. The dividend is payable April 28, 2026.
Approximately 510,605 shares of common stock are expected to be issued; no fractional shares will be issued and fractional entitlements will be paid in cash calculated at $2.38 per fractional share.
NeurAxis (NYSE: NRXS) reported strong revenue growth and strategic commercial wins for 4Q25 and FY2025. Revenue grew 27% in 4Q25 to $968k and 33% for FY2025 to $3.6M. Operating loss widened to $1.7M in 4Q25 and $7.8M for FY2025; cash was $5.0M at year-end.
Key commercial milestones include a Category I CPT code effective Jan 1, 2026, a VA Federal Supply Schedule contract, expanded FDA clearance for IB-Stim for abdominal pain in patients 8+ years, and post-year At-The-Market proceeds of $2.6M.
NeurAxis (NYSE American: NRXS) will report summarized fourth quarter and full year 2025 results for the period ended December 31, 2025, on Thursday, March 19, 2026, before market open.
The company will host a conference call and live webcast on March 19, 2026 at 9:00am ET; webcast and replay will be available in the Investor Relations section of the company's website. Participants can submit questions via the webcast portal or by emailing NRXS@lythampartners.com.
NeurAxis (NYSE American: NRXS) announced that an AMA Category I CPT code for Percutaneous Electrical Nerve Field Stimulation (PENFS) is now in effect as of Jan. 8, 2026. The code establishes a permanent, nationally recognized coding and billing pathway for NeurAxis’ IB-Stim therapy, signaling broad clinical acceptance and meeting AMA criteria for widespread utilization and clinical efficacy. Management said the code should improve payer alignment, reimbursement predictability, and scalability across health systems, potentially accelerating patient access and supporting long-term commercial growth. Management will present at the Lytham Partners Healthcare Investor Summit on Jan. 15, 2026.
NeurAxis (NYSE American: NRXS) announced new medical policy coverage from a major national health insurer for Percutaneous Electrical Nerve Field Stimulation (PENFS), adding approximately 45 million covered lives and bringing PENFS total national coverage to roughly 100 million covered lives.
The company’s FDA-cleared IB-Stim is approved for patients 8 years and older with functional abdominal pain related to IBS and functional dyspepsia. NeurAxis noted a Category I CPT code effective January 1, 2026, incorporation of PENFS into national clinical guidelines, and a strengthened balance sheet as positioning factors for expected revenue growth and margin expansion.
NeurAxis (NYSE American: NRXS) was awarded a Veterans Affairs Federal Supply Schedule contract effective December 1, 2025, listing its IB-Stim device as the first product on the FSS.
The award creates a federal commercial pathway into the VA health system, which serves nearly 7 million active patients annually. IB-Stim is an FDA-cleared percutaneous electrical nerve field stimulator for functional abdominal pain, approved for patients age 8 and older and described as the only FDA-cleared therapy for functional dyspepsia (FD). The company cited a Category I CPT code effective January 1, 2026 and said it will dedicate sales resources to VA channels to support commercialization into 2026.
NeurAxis (NYSE:NRXS) announced new medical policy coverage for Percutaneous Electrical Nerve Field Stimulation (PENFS) in Michigan, adding approximately 566,000 covered lives and bringing estimated national coverage to about 55 million lives.
The policy gives roughly 82% of commercially insured pediatric beneficiaries in Michigan access to PENFS. IB-Stim is FDA-cleared for functional abdominal pain related to IBS and Functional Dyspepsia for patients aged 8+. A Category I CPT code becomes effective January 1, 2026, and management cites ongoing payer discussions and a strengthened balance sheet to support expected revenue growth.
NeurAxis (NYSE American: NRXS) reported third quarter 2025 results and operational milestones on November 11, 2025. Revenues rose 22% year-over-year to $811,000 and unit deliveries increased ~38% year-over-year. Gross margin declined to 83.3% from 85.4% due to higher discounting and expired inventory. Operating expenses were $2.8M and operating loss was $2.1M, wider than a year earlier. Cash was $4.4M at September 30, 2025, with an additional $2.8M raised in October 2025 via an ATM offering and warrant exercises.
Key operational wins include multiple FDA clearances (expanded IB-Stim indications to ages 8–21, allowance of 4 devices per patient, FD indication with nausea, and 510(k) for RED), a new CPT Category I code effective January 1, 2026, and expanded covered lives to ~55 million.
NeurAxis (NYSE: NRXS) will release its third quarter 2025 financial results for the period ended September 30, 2025, on Tuesday, November 11, 2025 before market open.
The company will host a conference call and live webcast the same day at 9:00 a.m. Eastern Time. Webcast access and a replay will be available in the Investor Relations section at https://ir.neuraxis.com/ and at the provided media-server link. Participants may submit questions via the webcast portal or by emailing NRXS@lythampartners.com.
NeurAxis (NYSE:NRXS) received FDA 510(k) clearance for its percutaneous electrical nerve field stimulation (PENFS) device to treat functional abdominal pain associated with functional dyspepsia (FD) and FD-related nausea in patients aged 8 years and older on October 24, 2025. The FDA reviewed randomized trials and real-world evidence, extrapolating pediatric data to adults. This is described as the first FDA clearance for a treatment addressing adult functional dyspepsia. NeurAxis noted the new indication will use the Category I CPT code effective January 1, 2026 to report PENFS procedures.